TGFB1 and kidney disorder: While the lack of success of anti-TGF-β antibodies for kidney disease therapy may be multifactorial, a key factor may involve the complex and pleiotropic cellular actions of TGF-β that are carried out in a cell type- and context-dependent manner, posing a significant clinical challenge.